Inhibiting an enzyme in the brains of newborns suffering from oxygen and blood flow deprivation stops a type of brain damage that is a leading cause of cerebral palsy, mental retardation and death, according to researchers at Cincinnati Children's Hospital Medical Center.

Hepatic injury caused by ischemia/reperfusion (I/R) has been proposed as a key clinical problem associated with liver transplantation and major liver surgery.

Hepatic ischemia reperfusion injury remains a significant problem for hepatic surgical procedures and also remains a limitation of liver transplantation. It is important to reduce ischemia reperfusion injury. Oxygen free radicals, produced on reperfusion, play a critical role in the injury caused by ischemia-reperfusion.

While the results of the study did not show a statistically significant difference in ischemic events among any of the four doses of apixaban evaluated, trends emerged that support further study, according to researchers at the Duke Clinical Research Institute.

Professor Dan Atar, the Coordinating Investigator of the F.I.R.E. (FX06 In ischemia and REperfusion) trial, a Phase II clinical study of FX06, will present the results of the trial at 12-noon on September 2nd in the Hot Line III Session at the European Society of Cardiology Congress in Munich, Germany.

Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.